$LXRX

$1.49 +$0.01 (0.34%) Close

$LXRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 445.0M shares outstanding

Who owns LXRX?

By type of holder

Institutions 81.8% Insiders 18.2% Everyone else 0.0%

Concentration Top 10 holders own 138.2%

Artal Group S.A. 39.4% · Artal Participations S.a r.l. 30.6%

Institutional ownership

81.8%

+9.1 pts vs last qtr

Institutional holders

148

+12 vs last qtr

Net shares bought

+40.5M

by institutions in Q2 2026

New / sold out

44 / 32

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Artal Group S.A. +20.4M
BlackRock, Inc. +14.0M

Biggest sellers in Q2 2026

Millennium Management LLC −3.8M
Jane Street Group, LLC SOLD OUT −2.7M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Lexicon Pharmaceuticals, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2017–FY2025

+245.0%

+16.74% a year

Each share's claim on the business

−71.0%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

$10.7M vs $111M

over 9 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years76% 3–5 years0% 1–3 years18% Under 1 year5%

Quarterly turnover

12.5%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting LXRX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
AG Artal Group S.A.	175.2M	39.36%	+20.4M (+13.2%)	≤2021	45.2%
Shares held by quarter Peak holding175.2M (Q2'26) Change over 8 quarters+39.0M Share of the company39.360% Artal Group S.A.'s full portfolio →
F FMR LLC	51.8M	11.64%	+6.7M (+14.9%)	≤2021	0.0%
Shares held by quarter Peak holding52.0M (Q4'24) Change over 8 quarters+1.9M Share of the company11.640% FMR LLC's full portfolio →

Artal Group S.A.

175.2M

% of company

39.36%

Change vs last qtr

+20.4M (+13.2%)

Held since

≤2021

FMR LLC

51.8M

% of company

11.64%

Change vs last qtr

+6.7M (+14.9%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding Lexicon Pharmaceuticals, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting LXRX on Form N-PORT; together they hold 15.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FG Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust	$46.5M	20.7M	4.64%	0.05%	August 31, 2026
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$17M	7.1M	1.59%	0.00%	June 30, 2026

Fidelity Growth Company Fund

Fidelity Mt. Vernon Street Trust

Position value

$46.5M

% of company

4.64%

% of the fund

0.05%

As of

August 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$17M

% of company

1.59%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Lexicon Pharmaceuticals, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AP Artal Participations S.a r.l. Insider	136.2M	30.61%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company30.610% Artal Participations S.a r.l.'s insider activity →
DR Debbane Raymond Insider	110.2M	24.77%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company24.770% Debbane Raymond's insider activity →

Artal Participations S.a r.l.

Insider

136.2M

% of company

30.61%

Change vs last qtr

—

Held since

—

Debbane Raymond

Insider

110.2M

% of company

24.77%

Change vs last qtr

—

Held since

—

17 more holders behind a free account

See every insider and 5%+ holder of Lexicon Pharmaceuticals, Inc..

Comments